admin

The REC-CAGEFREE I randomized trial revealed disappointing results regarding the use of drug-coated balloon (DCB) angioplasty as the initial strategy for de novo coronary artery stenoses. In comparison to stenting, DCB with rescue use of drug-eluting stents (DES) nearly doubled the composite 24-month rate of cardiovascular death, target vessel myocardial infarction (MI), and clinically and
0 Comments
The recent financial troubles at WazirX have caused a stir among users, with many urgently withdrawing their Indian Rupee (INR) balances from the platform. After the unfreezing of 66 percent of users’ INR balances on August 26, there was initially a surge in withdrawals. However, this momentum has since slowed down. Co-founder Nischal Shetty advised
0 Comments
Recently, the wife of a Tory councillor found herself in legal trouble after pleading guilty to publishing written material to stir up racial hatred. Lucy Connolly, a childminder from Northampton, made a post on a social media platform, expressing inflammatory views about asylum seekers. Her post, which called for mass deportation and violence against asylum
0 Comments
When examining the vast expanse of our galaxy, it is easy to be captivated by the beauty of the stars and celestial bodies. However, upon closer inspection, researchers have discovered intriguing traces of a tumultuous past that hint at a violent history. Recent findings from an international team of researchers using data from the Gaia
0 Comments
The Asia-Pacific markets experienced a mixed day on Monday as investors digested China’s business activity numbers released over the weekend. China’s official purchasing managers’ index data for August showed a decline in the manufacturing PMI to a six-month low of 49.1, indicating a faster contraction compared to the previous month. This missed the forecast from
0 Comments
Patients with atrial fibrillation (Afib) and stable coronary artery disease (CAD) often face complex treatment decisions regarding antithrombotic therapy. A recent study, the EPIC-CAD trial, compared the efficacy of edoxaban monotherapy to dual antithrombotic therapy in this patient population. The findings of this trial, presented at the European Society of Cardiology (ESC) meeting and simultaneously
0 Comments